Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: A systematic review and network meta-analysis

Alfred D. Nelson, Michael Camilleri, Sakkarin Chirapongsathorn, Priya Vijayvargiya, Nelson Valentin, Andrea Shin, Patricia J. Erwin, Zhen Wang, Mohammad H Murad

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis. Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC. Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points. Data extraction and synthesis Two investigators independently evaluated all full-text articles that met inclusion criteria and extracted data for primary and secondary end points, risk of bias and quality of evidence. Outcomes Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. Secondary end points were change from baseline (δb) in the number of SBM/week and δb CSBM/week. Results Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All prespecified end points were unavailable in four polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/week end point. No drug was superior at improving the primary end points on network metaanalysis. Bisacodyl appeared superior to the other drugs for the secondary end point, δb in number of SBM/ week. Conclusions Current drugs for CIC show similar efficacy. Bisacodyl may be superior to prescription medications for δb in the number of SBM/week in CIC.

Original languageEnglish (US)
JournalGut
DOIs
StateAccepted/In press - Jun 10 2016

Fingerprint

Bisacodyl
Constipation
prucalopride
Pharmacology
elobixibat
Placebos
Pharmaceutical Preparations
Information Storage and Retrieval
MEDLINE
Prescriptions
Network Meta-Analysis
Randomized Controlled Trials
Research Personnel
Drug Therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation : A systematic review and network meta-analysis. / Nelson, Alfred D.; Camilleri, Michael; Chirapongsathorn, Sakkarin; Vijayvargiya, Priya; Valentin, Nelson; Shin, Andrea; Erwin, Patricia J.; Wang, Zhen; Murad, Mohammad H.

In: Gut, 10.06.2016.

Research output: Contribution to journalArticle

Nelson, Alfred D. ; Camilleri, Michael ; Chirapongsathorn, Sakkarin ; Vijayvargiya, Priya ; Valentin, Nelson ; Shin, Andrea ; Erwin, Patricia J. ; Wang, Zhen ; Murad, Mohammad H. / Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation : A systematic review and network meta-analysis. In: Gut. 2016.
@article{27ee8426834643fe96118683d0a90f47,
title = "Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: A systematic review and network meta-analysis",
abstract = "Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis. Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC. Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points. Data extraction and synthesis Two investigators independently evaluated all full-text articles that met inclusion criteria and extracted data for primary and secondary end points, risk of bias and quality of evidence. Outcomes Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. Secondary end points were change from baseline (δb) in the number of SBM/week and δb CSBM/week. Results Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All prespecified end points were unavailable in four polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/week end point. No drug was superior at improving the primary end points on network metaanalysis. Bisacodyl appeared superior to the other drugs for the secondary end point, δb in number of SBM/ week. Conclusions Current drugs for CIC show similar efficacy. Bisacodyl may be superior to prescription medications for δb in the number of SBM/week in CIC.",
author = "Nelson, {Alfred D.} and Michael Camilleri and Sakkarin Chirapongsathorn and Priya Vijayvargiya and Nelson Valentin and Andrea Shin and Erwin, {Patricia J.} and Zhen Wang and Murad, {Mohammad H}",
year = "2016",
month = "6",
day = "10",
doi = "10.1136/gutjnl-2016-311835",
language = "English (US)",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation

T2 - A systematic review and network meta-analysis

AU - Nelson, Alfred D.

AU - Camilleri, Michael

AU - Chirapongsathorn, Sakkarin

AU - Vijayvargiya, Priya

AU - Valentin, Nelson

AU - Shin, Andrea

AU - Erwin, Patricia J.

AU - Wang, Zhen

AU - Murad, Mohammad H

PY - 2016/6/10

Y1 - 2016/6/10

N2 - Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis. Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC. Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points. Data extraction and synthesis Two investigators independently evaluated all full-text articles that met inclusion criteria and extracted data for primary and secondary end points, risk of bias and quality of evidence. Outcomes Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. Secondary end points were change from baseline (δb) in the number of SBM/week and δb CSBM/week. Results Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All prespecified end points were unavailable in four polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/week end point. No drug was superior at improving the primary end points on network metaanalysis. Bisacodyl appeared superior to the other drugs for the secondary end point, δb in number of SBM/ week. Conclusions Current drugs for CIC show similar efficacy. Bisacodyl may be superior to prescription medications for δb in the number of SBM/week in CIC.

AB - Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis. Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC. Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points. Data extraction and synthesis Two investigators independently evaluated all full-text articles that met inclusion criteria and extracted data for primary and secondary end points, risk of bias and quality of evidence. Outcomes Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. Secondary end points were change from baseline (δb) in the number of SBM/week and δb CSBM/week. Results Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All prespecified end points were unavailable in four polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/week end point. No drug was superior at improving the primary end points on network metaanalysis. Bisacodyl appeared superior to the other drugs for the secondary end point, δb in number of SBM/ week. Conclusions Current drugs for CIC show similar efficacy. Bisacodyl may be superior to prescription medications for δb in the number of SBM/week in CIC.

UR - http://www.scopus.com/inward/record.url?scp=84979007773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979007773&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2016-311835

DO - 10.1136/gutjnl-2016-311835

M3 - Article

C2 - 27287486

AN - SCOPUS:84979007773

JO - Gut

JF - Gut

SN - 0017-5749

ER -